

**Curriculum vitae RIGHI LUISELLA**  
**(March 2023)**

**Personal details**

Born in 1974

Nationality: Italy

Email: luisella.righi@unito.it

Website: //

ORCID ID: 0000-0002-8927-204; Scopus ID: 7005748711

**Educations**

<b>Start Date MM/YYYY</b>	<b>Completion Date MM/YYYY</b>	<b>FIELD OF STUDY</b>	<b>DEGREE</b>	<b>INSTITUTION AND LOCATION</b>
10/1993	07/1999	GENERAL MEDICINE	MD	UNIVERSITY OF TORINO, ITALY
01/2000	12/2003	ONCOLOGY	PhD	UNIVERSITY OF TORINO, ITALY
10/2004	10/2009	SURGICAL PATHOLOGY	Postgraduate School	UNIVERSITY OF TORINO, ITALY

**Professional experiences and current position**

February-2010-October 2010	Non-permanent employment as consultant of Surgical Pathology at Institute for Cancer Research and Treatment, Candiolo (Turin, ITALY)
October 2010-September 2013	Non-confirmed Assistant Professor at the University of Turin, Department of Oncology; Orbassano (Turin, ITALY)
October 2013-July-2018	Confirmed Assistant Professor at the University of Turin, Department of Oncology, Pathology Unit at San Luigi Hospital, Orbassano (Turin, ITALY)
17 July 2018-to date	Associate Professor at the University of Turin, Department of Oncology, Pathology Unit at San Luigi Hospital Orbassano (Turin, ITALY)

**Participation to Directive Boards of Scientific Societies and/or Institutions:**

Member of the International Association of Study of Lung Cancer (IASLC)

Member of the European Society of Pathology (ESP)

Member of the Associazione Italiana Oncologi Medici (AIOM)

Member of the Società Italiana di Anatomia Patologica e Citologia (SIAPEC); contact person of the italian group of pleuro-pulmonar pathologists (GIPP).

**Honors**

//

**Teaching activity:**

- AA 2018/2019-today: Teaching activity in Surgical Pathology for Medicine Students; School for Technician.
- 2010-today: tutor for Undergraduate Students of Medicine, trainees in Surgical Pathology Unit;
- AA 2010/2011-today: Teaching activity in Oncology for the Postgraduate School in Surgical Pathology, Thoracic Surgery, Respiratory Disease

**Research main topics**

As a pathologist I'm daily dedicated to diagnostic histopathology and cytology of thoracic oncology together with diagnostic immunohistochemistry and molecular biology techniques applied to histo- and cytopathology. As a researcher my fields of interest are mainly focused on translational studies of histology, immunohistochemistry and molecular pathology applied to thoracic tumors: in particular, since 2007 I've been studying the application of immunocytochemistry and molecular biology to identify new biomarkers of neoplasia and/or characterise the

phenotypic and molecular profile of various human thoracic tumors, such as non-small cell lung cancer, malignant pleural mesothelioma and neuroendocrine tumors, establishing correlation with clinico-pathological parameters, response to therapy and prognosis.

In the Department of Oncology at San Luigi Hospital I work in collaboration with both basic science researchers of the Oncology Department, University of Turin and clinical oncologists of the Thoracic Oncology Unit at San Luigi Hospital (Orbassano, Turin, Italy) for a multidisciplinary approach to NSCLC pathogenesis, progression and treatment

#### Main projects as PI:

2011: Young Researcher grant (GR-2011-02348356) from the Ministry of Health (Rome) and Regione Piemonte (Turin). PI: Righi L.

2019: Fondazione CRT

#### Bibliometry (2001-present) ([www.scopus.com](http://www.scopus.com))

3667 Citations by 2,954 documents; 129 Documents; 36 h-index (03/2023)

#### Publications

##### **MOST RECENT PUBLICATIONS (last two years) selected from more than 120 peer-reviewed publications**

- Bironzo P, Primo L, Novello S, **Righi L**, Candeloro S, Manganaro L, Bussolino F, Pirri F, Scagliotti GV. Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response. *CLIN LUNG CANCER* 2022 Sep; 23: e347.

- Mariniello A, Tabbò F, Indellicati D, Tesauro M, Rezmives NA, Reale ML, Listì A, Capelletto E, Carnio S, Bertaglia V, Mecca C, Consito L, De Filippis M, Bungaro M, Paratore C, Di Maio M, Passiglia F, **Righi L**, Sangiolo D, Novello S, Geuna M, Bironzo P. Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer. *CELLS-BASEL* 2022 Oct; 11;

- Tabbò F, Muscarella LA, Gobbi E, Trombetta D, Castellana S, Rigutto A, Galetta D, Maiello E, Martelli O, Tiseo M, Scotti V, Ghilardi L, Gregorc V, Sergi C, Pilotto S, Del Conte A, Cappuzzo F, Cortinovis D, Osman G, Bareggi C, Di Maio M, Rossi A, Rossi G, Bria E, Volante M, Scagliotti GV, Graziano P, Novello S, **Righi L**. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences. *EUR J CANCER* 2022 Oct; 174: 200.

- Sculco M, La Vecchia M, Aspesi A, Clavenna MG, Salvo M, Borgonovi G, Pittaro A, Witel G, Napoli F, Listì A, Grosso F, Libener R, Maconi A, Rena O, Boldorini R, Giachino D, Bironzo P, Maffè A, Ali G, Elefanti L, Menin C, **Righi L**, Tampieri C, Scagliotti GV, Dianzani C, Ferrante D, Migliore E, Magnani C, Mirabelli D, Matullo G, Dianzani I. Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitest Approach: A Ten-Year-Long Experience. *DIAGNOSTICS* 2022 Jul; 12;

- Napoli F, Rapa I, Izzo S, Rigutto A, Libener R, Riganti C, Bironzo P, Taulli R, Papotti M, Volante M, Scagliotti G, **Righi L**. Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. *VIRCHOWS ARCH* 2022 Aug; 481: 233;

- Vavala T, Malapelle U, Veggiani C, Ludovini V, Papotti M, Leone A, Graziano P, Minari R, Bono F, Sapino A, Manotti L, Troncone G, Pisapia P, Girlando S, Buffoni L, **Righi L**, Colantonio I, Bertetto O, Novello S. Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice. *J CLIN PATHOL* 2022 Apr; 75: 234;

- Luca C, Pepe F, Pisapia P, Iaccarino A, **Righi L**, Listì A, Russo G, Campione S, Pagni F, Nacchio M, Conticelli F, Russo M, Fabozzi T, Vigliar E, Bellevicine C, Rocco D, Laudati S, Iannaci G, Daniele B, Gridelli C, Cortinovis DL, Novello S, Molina-Vila MA, Rosell R, Troncone G, Malapelle U. RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center. *PERS MED* 2022 Sep; 19: 395

- Salaroglio IC, Belisario DC, Bironzo P, Ananthanarayanan P, Ricci L, Digiovanni S, Fontana S, Napoli F, Sandri A, Facolmatà C, Libener R, Comunanza V, Grosso F, Gazzano E, Leo F, Taulli R, Bussolino F, **Righi L**, Papotti M, Novello S, Scagliotti G, Riganti C, Kopecka J. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. *J Exp Clin Cancer Res* 2022.

- **Righi L**, Volante M, Papotti M. Small-Cell Carcinoma of the Lung: What We Learned about It? *Acta Cytol.* 2021.

- Liberini V, Mariniello A, **Righi L**, Capozza M, Delcuratolo MD, Terreno E, Farsad M, Volante M, Novello S, Deandrea D. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. *Cancers (Basel).* 2021.

- Passiglia F, Reale ML, Cetoretta V, Parlagreco E, Jacobs F, Listì A, **Righi L**, Bironzo P, Novello S, Scagliotti GV. Repositioning PARP inhibitors in the treatment of thoracic malignancies. *Cancer Treat Rev.* 2021.
- Napoli F, Listì A, Zambelli V, Witel G, Bironzo P, Papotti M, Volante M, Scagliotti G, **Righi L**. Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. *Cancers (Basel).* 2021
- Bironzo P, Reale ML, Sperone T, Tabbò F, Caglio A, Listì A, Passiglia F, Di Maio M, **Righi L**, Bussolino F, Scagliotti GV, Novello S. Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. *Cancers (Basel).* 2021
- Anobile DP, Bironzo P, Picca F, Lingua MF, Morena D, **Righi L**, Napoli F, Papotti MG, Pittaro A, Di Nicolantonio F, Gigliotti C, Bussolino F, Comunanza V, Guerrera F, Sandri A, Leo F, Libener R, Aviles P, Novello S, Taulli R, Scagliotti GV, Riganti C. Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. *Cancers (Basel).* 2021
- Bertero L, **Righi L**, Collemi G, Koelsche C, Hou Y, Stichel D, Schrimpf D, Flucke U, Petersen I, Vokuhl C, Fröhling S, Bironzo P, Scagliotti GV, Cassoni P, Papotti M, von Deimling A. DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. *J Mol Diagn.* 2021
- Carrà G, Ermondi G, Riganti C, **Righi L**, Caron G, Menga A, Capelletto E, Maffeo B, Lingua MF, Fusella F, Volante M, Taulli R, Guerrasio A, Novello S, Brancaccio M, Piazza R, Morotti A.  $\text{I}\kappa\text{B}\alpha$  targeting promotes oxidative stress-dependent cell death. *J Exp Clin Cancer Res.* 2021
- Malapelle U, Pilotto S, Passiglia F, Pepe F, Pisapia P, **Righi L**, Listì A, Bironzo P, Belluomini L, Tabbò F, Reale ML, Russo G, De Luca C, Novello S, Troncone G. Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. *Crit Rev Oncol Hematol.* 2021
- Zito Marino F, Ali G, Facchinetti F, **Righi L**, Fontanini G, Rossi G, Franco R. Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy. *Expert Rev Anticancer Ther.* 2021
- Malapelle U, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listì A, Loupakis F, Pagni F, Pietrantonio F, Pilotto S, **Righi L**, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. *Eur J Cancer.* 2021
- Bersani F, Morena D, Picca F, Morotti A, Tabbò F, Bironzo P, **Righi L**, Taulli R. Future perspectives from lung cancer pre-clinical models: new treatments are coming? *Transl Lung Cancer Res.* 2020
- De Luca C, Pepe F, Iaccarino A, Pisapia P, **Righi L**, Listì A, Greco L, Gragnano G, Campione S, De Dominicis G, Pagni F, Sgariglia R, Nacchio M, Tufano R, Conticelli F, Vigliar E, Bellevicine C, Cortinovis DL, Novello S, Molina-Vila MA, Rosell R, Troncone G, Malapelle U. RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. *Cancers (Basel).* 2021
- Passiglia F, Bironzo P, **Righi L**, Listì A, Arizio F, Novello S, Volante M, Scagliotti GV. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. *Clin Lung Cancer.* 2021